New UN documents today provide proposals and options to meet a global pledge to share fairly some of the multi-trillion-dollar revenues and other benefits derived from products produced, improved or related to the use of “digital sequence information on genetic resources (DSI)” – the DNA sequences of plants, animals and microbes.
A positive outcome would help address an outstanding gap in efforts to share the benefits derived from the use of genetic resources. A new multilateral mechanism was pledged by the UN Convention on Biological Diversity’s 196 Parties in 2022 at COP 15.
Agreement is needed on several questions, including which industrial sectors using DSI should share its benefits.
Top candidates include sectors creating and improving drugs, cosmetics, seeds and agricultural biotechnology.
Final negotiations
The documents are published six weeks before nations meet in Montreal 12-16 August for final negotiations within the DSI intergovernmental negotiating group before the matter comes up for decision at the UN biodiversity Conference (COP 16) in October, in Cali, Colombia.
Co-Chairs of the negotiations, Mphatso Kalemba of Malawi and William Lockhart of the UK, note the that sectors that depend most on DSI generate from “one to a few trillion dollars annually;” just 0.1% of US $1 trillion would yield $1 billion for the global fund; 1% would amount to $10 billion.
Envisioned uses of the funds include supporting the conservation and sustainable use of nature, including related activities of Indigenous Peoples and Local Communities, and building capacity worldwide to generate and use DSI.
Producers of products
As noted in the meeting’s preparatory documents: “While all producers of products developed through the use of DSI or all companies operating in sectors that are highly dependent on DSI would be encouraged to contribute, the main focus would be on large and transnational producers or companies.”
“The scale of the contributions to the fund should take into account the overall intended scale of the fund, the number of contributors, the degree to which revenue generated is dependent on the use of DSI, and the potential impact of the contribution on business activity and consumers.”
As well, adds an information synthesis, contributions should be “proportionate and reasonable, in the sense that businesses are not burdened with unsustainable costs, and that additional costs are not so significant that they are passed through to consumers in a way that might generate new inflationary pressures.”
Trigger points
Potential trigger points for contributions identified by the Co-Chairs:
- When a product developed through the use of DSI is placed on the market, users would be expected to contribute
- When revenue is generated in a sector highly dependent on the use of DSI, companies would be expected to contribute a proportion of their total revenue generated
Various options for disbursing funds are addressed, as well as options for governance of the mechanism, and how to share non-monetary benefits of DSI-related science, including capacity building, technology transfer, research results, and joint research partnerships.
Global fund
Production of the documents stem from a 2022 agreement by the UN Convention on Biological Diversity’s 196 Parties to establish a global fund within a new multilateral mechanism for DSI benefit sharing.
Looking forward, CBD’s DSI working group negotiators will make recommendations to be taken up at the next biodiversity summit, which includes COP16 (Cali, Colombia, 21 October - 1 November).
David Cooper, CBD’s Acting Executive Secretary, says: “Until now, users of information on genetic resources have shared little of the profits generated from their use.”
Options for mechanism
“The need to address this issue was settled at COP-15 in Montreal in 2022 as part of the deal that also included the Kunming-Montreal Global Biodiversity Framework – ‘the Biodiversity Plan.’ These documents consider the many questions and challenges ahead, and propose some options for the mechanism’s efficient, effective operation, including a new fund that could support the those who are protecting biodiversity around the world, especially indigenous peoples and local communities around the world.”
“We have faith that the goodwill and positive and constructive spirit of compromise Parties have shown to date on this issue will continue through the negotiations in Montreal and Cali,” he adds.
Ms. Kalemba says: “The world has been presented with an opportunity to mobilize additional resources for biodiversity conservation and sustainable use whilst enhancing benefits from the use of DSI through this mechanism and its fund. I hope that delegates will work hard in Montreal to unpack that solution to the world.”
Adds Mr. Lockhart: “It has been a privilege to work with Governments, researchers, indigenous peoples, NGOs and others to prepare these proposals. By sharing the benefits from the use of DSI, and using those benefits to protect nature, we will collectively ensure that nature’s wonders remain available to the next generation of scientists. We are looking forward to a positive round of negotiations in Montreal ahead of COP16.”
Digital Sequence Information (DSI)
DNA contains the genetic information that instructs living things on how to grow and function. By analysing digital versions of the DNA of plants, animals, and microbes (such as bacteria), scientists identify genes to help create or improve medicines, skincare products, foods and nutritional supplements, feed for animals, bioplastics, and textiles, among other products.
Once a useful gene is found, scientists can create a version in the lab and insert it into microbes like bacteria or yeast, which then act like tiny factories, using the new genetic instructions to produce the desired compounds.
In short, by reading and understanding DNA, scientists discover and produce new ingredients and compounds to create or improve valuable products.
Other parts of market
Other parts of the DSI-related market worldwide include laboratory equipment (hardware), information technology programmes / platforms (software), and commercial production of DSI information.
The use of DSI varies across sectors, with use by pharmaceutical and cosmetics firms high relative to others.
The CBD Parties’ criteria for DSI benefit sharing agreed to in 2022, included:
- Efficient, feasible, and practical, without undue complexity or burden
- Monetary and non-monetary benefits outweigh associated costs
- Effective, fair and equitable benefit sharing
- Clear legal frameworks for both providers and users of DSI
- No impediment posed to scientific research and innovation, and support principles of open access to scientific data where appropriate
- Aligns with existing international agreements and conventions, and complements and reinforces related instruments; and
- Respects and upholds the rights of indigenous peoples and local communities, especially regarding traditional knowledge associated with genetic resources
Among concerns to be addressed:
- Potential negative impacts on open access to data, research and innovation
- The costs and administrative complexities of managing funds
- Governance of the mechanism, the global fund, and related data, and
- The role of science in non-monetary benefit-sharing
The full documents released today to the CBDs 196 Parties (available at https://bit.ly/3zhS7jK):
* Synthesis of information for the further development of the multilateral mechanism established under (COP15) decision 15/9, including elements of a draft recommendation (CBD/WGDSI/2/2)
* Reflections of the Co-Chairs on the possible elements identified by the Working Group on Benefit-sharing from the Use of Digital Sequence Information on Genetic Resources at its first meeting (CBD/WGDSI/2/2/Add.1 ), and
* Executive summary of the studies commissioned pursuant to decision 15/9 (CBD/WGDSI/2/2/Add.2)
No comments yet